Pub Date : 2024-07-16DOI: 10.1681/ASN.0000000000000440
Alfonso Eirin, Sarosh Siddiqi, Autumn G Hughes, Yamei Jiang, Xiang-Yang Zhu, Sara Kazeminia, Bo Lu, Li Xing, Brandon Lu, Hui Tang, Ailing Xue, Amir Lerman, Stephen C Textor, Lilach O Lerman
{"title":"Renovascular Disease and Mitochondrial Dysfunction in Human Mesenchymal Stem Cells.","authors":"Alfonso Eirin, Sarosh Siddiqi, Autumn G Hughes, Yamei Jiang, Xiang-Yang Zhu, Sara Kazeminia, Bo Lu, Li Xing, Brandon Lu, Hui Tang, Ailing Xue, Amir Lerman, Stephen C Textor, Lilach O Lerman","doi":"10.1681/ASN.0000000000000440","DOIUrl":"10.1681/ASN.0000000000000440","url":null,"abstract":"","PeriodicalId":17217,"journal":{"name":"Journal of The American Society of Nephrology","volume":null,"pages":null},"PeriodicalIF":10.3,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141627081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-12DOI: 10.1681/ASN.0000000000000439
Francesco Bellomo, Sara Pugliese, Sara Cairoli, Patrick Krohn, Cristiano De Stefanis, Roberto Raso, Laura Rita Rega, Anna Taranta, Ester De Leo, Andrea Ciolfi, Nicolò Cicolani, Stefania Petrini, Alessandro Luciani, Bianca Maria Goffredo, Ottavia Porzio, Olivier Devuyst, Carlo Dionisi-Vici, Francesco Emma
{"title":"Ketogenic Diet and Progression of Kidney Disease in Animal Models of Nephropathic Cystinosis.","authors":"Francesco Bellomo, Sara Pugliese, Sara Cairoli, Patrick Krohn, Cristiano De Stefanis, Roberto Raso, Laura Rita Rega, Anna Taranta, Ester De Leo, Andrea Ciolfi, Nicolò Cicolani, Stefania Petrini, Alessandro Luciani, Bianca Maria Goffredo, Ottavia Porzio, Olivier Devuyst, Carlo Dionisi-Vici, Francesco Emma","doi":"10.1681/ASN.0000000000000439","DOIUrl":"10.1681/ASN.0000000000000439","url":null,"abstract":"","PeriodicalId":17217,"journal":{"name":"Journal of The American Society of Nephrology","volume":null,"pages":null},"PeriodicalIF":10.3,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141600283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-12DOI: 10.1681/ASN.0000000000000436
J David Smeijer, Victor S Wasehuus, Neeraj Dhaun, Jose Luis Gorriz, Maria José Soler, Magnus Åstrand, Anne-Kristina Mercier, Peter J Greasley, Phil Ambery, Hiddo J L Heerspink
Background: Endothelin receptor antagonists (ERAs) reduce albuminuria but are limited by fluid retention risk, particularly in patients with chronic kidney disease (CKD). Combining ERAs with sodium-glucose cotransporter 2 (SGLT2) inhibitors, which have diuretic effects, offers a promising strategy to mitigate fluid retention. In this post-hoc analysis of the ZENITH-CKD trial, we assessed fluid dynamics in patients with CKD treated with the ERA zibotentan alone, and in combination with the SGLT2 inhibitor dapagliflozin.
Methods: In ZENITH-CKD, 508 patients with CKD (estimated glomerular filtration rate ≥ 20 mL/min/1.73m2 and a urinary albumin-to-creatinine ratio of 150-5000 mg/g) were randomized to treatment with placebo, dapagliflozin 10 mg plus placebo, zibotentan (0.25, 1.5 or 5 mg) plus dapagliflozin 10 mg and zibotentan 5 mg plus placebo. We evaluated correlations between changes in fluid retention markers and bioimpedance-measured extracellular fluid (ECF) in response to zibotentan treatment. We used Cox proportional hazards regression to assess the association between zibotentan/dapagliflozin treatment, baseline characteristics, and fluid retention, and the relationship between zibotentan plasma exposure and fluid retention.
Results: After 3 weeks of treatment with zibotentan 0.25, 1.5 or 5 mg plus dapagliflozin 10 mg, changes in body weight (β=0.36 [95%CI 0.26,0.45]) per kg, B-type natriuretic peptide (β=0.38 [95%CI 0.22, 0.54]) per doubling, and hemoglobin (β=-0.29 [95%CI -0.48, -0.10]) per g/dL were independently associated with changes in ECF. Higher doses of zibotentan were associated with significantly higher risk of fluid retention compared to dapagliflozin alone (zibotentan 5 mg HR 8.50 (95%CI 3.40, 21.30). The hazard ratio attenuated when zibotentan was combined with dapagliflozin (HR zibotentan/dapagliflozin 5/10 mg 3.09 [95%CI 1.08, 8.80], zibotentan/dapagliflozin 1.5/10 mg 2.70 [95%CI 1.44, 5.07] and zibotentan/dapagliflozin 0.25/10 mg HR 1.21 [95%CI 0.50, 2.91]). The risk of fluid retention was higher with higher zibotentan exposure and lower eGFR.
Conclusions: High doses of zibotentan were associated with a higher risk of fluid retention, which was attenuated with lower doses and the addition of dapagliflozin.
{"title":"Effects of Zibotentan Alone and in Combination with Dapagliflozin on Fluid Retention in Patients with CKD.","authors":"J David Smeijer, Victor S Wasehuus, Neeraj Dhaun, Jose Luis Gorriz, Maria José Soler, Magnus Åstrand, Anne-Kristina Mercier, Peter J Greasley, Phil Ambery, Hiddo J L Heerspink","doi":"10.1681/ASN.0000000000000436","DOIUrl":"10.1681/ASN.0000000000000436","url":null,"abstract":"<p><strong>Background: </strong>Endothelin receptor antagonists (ERAs) reduce albuminuria but are limited by fluid retention risk, particularly in patients with chronic kidney disease (CKD). Combining ERAs with sodium-glucose cotransporter 2 (SGLT2) inhibitors, which have diuretic effects, offers a promising strategy to mitigate fluid retention. In this post-hoc analysis of the ZENITH-CKD trial, we assessed fluid dynamics in patients with CKD treated with the ERA zibotentan alone, and in combination with the SGLT2 inhibitor dapagliflozin.</p><p><strong>Methods: </strong>In ZENITH-CKD, 508 patients with CKD (estimated glomerular filtration rate ≥ 20 mL/min/1.73m2 and a urinary albumin-to-creatinine ratio of 150-5000 mg/g) were randomized to treatment with placebo, dapagliflozin 10 mg plus placebo, zibotentan (0.25, 1.5 or 5 mg) plus dapagliflozin 10 mg and zibotentan 5 mg plus placebo. We evaluated correlations between changes in fluid retention markers and bioimpedance-measured extracellular fluid (ECF) in response to zibotentan treatment. We used Cox proportional hazards regression to assess the association between zibotentan/dapagliflozin treatment, baseline characteristics, and fluid retention, and the relationship between zibotentan plasma exposure and fluid retention.</p><p><strong>Results: </strong>After 3 weeks of treatment with zibotentan 0.25, 1.5 or 5 mg plus dapagliflozin 10 mg, changes in body weight (β=0.36 [95%CI 0.26,0.45]) per kg, B-type natriuretic peptide (β=0.38 [95%CI 0.22, 0.54]) per doubling, and hemoglobin (β=-0.29 [95%CI -0.48, -0.10]) per g/dL were independently associated with changes in ECF. Higher doses of zibotentan were associated with significantly higher risk of fluid retention compared to dapagliflozin alone (zibotentan 5 mg HR 8.50 (95%CI 3.40, 21.30). The hazard ratio attenuated when zibotentan was combined with dapagliflozin (HR zibotentan/dapagliflozin 5/10 mg 3.09 [95%CI 1.08, 8.80], zibotentan/dapagliflozin 1.5/10 mg 2.70 [95%CI 1.44, 5.07] and zibotentan/dapagliflozin 0.25/10 mg HR 1.21 [95%CI 0.50, 2.91]). The risk of fluid retention was higher with higher zibotentan exposure and lower eGFR.</p><p><strong>Conclusions: </strong>High doses of zibotentan were associated with a higher risk of fluid retention, which was attenuated with lower doses and the addition of dapagliflozin.</p>","PeriodicalId":17217,"journal":{"name":"Journal of The American Society of Nephrology","volume":null,"pages":null},"PeriodicalIF":10.3,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141600282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-10DOI: 10.1681/ASN.0000000000000442
Xue-Ping Wang, Stephanie M Mutchler, Rolando Carrisoza-Gaytan, Andrew J Nickerson, Catherine J Baty, Mohammad Al-Bataineh, Amber Vandevender, Tetsuji Morimoto, Priyanka Srinivasan, Roderick J Tan, Michael J Jurczak, Lisa M Satlin, Ossama B Kashlan
{"title":"Epithelial Na + Channel Activation after Bile Duct Ligation with Mineralocorticoid Receptor Blockade.","authors":"Xue-Ping Wang, Stephanie M Mutchler, Rolando Carrisoza-Gaytan, Andrew J Nickerson, Catherine J Baty, Mohammad Al-Bataineh, Amber Vandevender, Tetsuji Morimoto, Priyanka Srinivasan, Roderick J Tan, Michael J Jurczak, Lisa M Satlin, Ossama B Kashlan","doi":"10.1681/ASN.0000000000000442","DOIUrl":"10.1681/ASN.0000000000000442","url":null,"abstract":"","PeriodicalId":17217,"journal":{"name":"Journal of The American Society of Nephrology","volume":null,"pages":null},"PeriodicalIF":10.3,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141580094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Most of the world's adult population is latently infected by the BK polyomavirus. It causes asymptomatic infection in healthy individuals but emerged as a threat to kidney transplant recipients because of virus-associated nephropathy caused by immunosuppressive therapy. In these conditions, when a functional cellular response is impaired by immunosuppression, neutralizing antibodies may play a major role because they can directly prevent infection of target cells, independently of cell-mediated immunity, by binding to the viral particles. Studying the contribution of anti-BK virus neutralizing antibodies in viral control has long been hampered by the lack of convenient in vitro models, but major progress has been made in the past decade. The four BK virus genotypes have been demonstrated to behave as distinct serotypes. A low recipient neutralizing antibody titer against the donor's serotype before kidney transplant has been significantly associated with BK virus replication after transplant. Different mechanisms exploited by the BK virus to evade neutralizing antibodies have been described. Recent studies also support the potential benefit of administering intravenous Igs or monoclonal neutralizing antibodies as a therapeutic strategy, and more interestingly, this could also be used as preventive or preemptive therapy before advanced kidney damage has occurred. Besides, neutralizing antibodies could be induced by vaccination. In this review, we summarize accumulated knowledge on anti-BK virus neutralizing antibodies as well as their clinical importance and therapeutic potential for kidney transplant recipients.
世界上大多数成年人都潜伏感染了 BK 多瘤病毒。它在健康人中会引起无症状感染,但由于免疫抑制疗法引起的病毒相关性肾病,它已成为肾移植受者的一个威胁。在这些情况下,当细胞功能反应因免疫抑制而受损时,中和抗体可能会发挥重要作用,因为它们可以通过与病毒颗粒结合,直接阻止靶细胞感染,而不受细胞介导免疫的影响。长期以来,由于缺乏方便的体外模型,研究抗 BK 病毒中和抗体在病毒控制中的作用一直受到阻碍,但在过去十年中取得了重大进展。四种 BK 病毒基因型已被证明表现为不同的血清型。肾移植前受体针对供体血清型的中和抗体滴度低与移植后 BK 病毒复制有很大关系。已有研究描述了 BK 病毒逃避中和抗体的不同机制。最近的研究也支持将静脉注射 Igs 或单克隆中和抗体作为一种治疗策略的潜在益处,更有趣的是,这也可以在晚期肾损伤发生之前作为预防性或先发制人的治疗。此外,中和抗体还可以通过疫苗接种来诱导。在这篇综述中,我们总结了有关抗 BK 病毒中和抗体的累积知识及其对肾移植受者的临床重要性和治疗潜力。
{"title":"Neutralizing Antibodies Targeting BK Polyomavirus: Clinical Importance and Therapeutic Potential for Kidney Transplant Recipients.","authors":"Francois Helle, Aurélien Aubry, Virginie Morel, Véronique Descamps, Baptiste Demey, Etienne Brochot","doi":"10.1681/ASN.0000000000000457","DOIUrl":"https://doi.org/10.1681/ASN.0000000000000457","url":null,"abstract":"<p><p>Most of the world's adult population is latently infected by the BK polyomavirus. It causes asymptomatic infection in healthy individuals but emerged as a threat to kidney transplant recipients because of virus-associated nephropathy caused by immunosuppressive therapy. In these conditions, when a functional cellular response is impaired by immunosuppression, neutralizing antibodies may play a major role because they can directly prevent infection of target cells, independently of cell-mediated immunity, by binding to the viral particles. Studying the contribution of anti-BK virus neutralizing antibodies in viral control has long been hampered by the lack of convenient in vitro models, but major progress has been made in the past decade. The four BK virus genotypes have been demonstrated to behave as distinct serotypes. A low recipient neutralizing antibody titer against the donor's serotype before kidney transplant has been significantly associated with BK virus replication after transplant. Different mechanisms exploited by the BK virus to evade neutralizing antibodies have been described. Recent studies also support the potential benefit of administering intravenous Igs or monoclonal neutralizing antibodies as a therapeutic strategy, and more interestingly, this could also be used as preventive or preemptive therapy before advanced kidney damage has occurred. Besides, neutralizing antibodies could be induced by vaccination. In this review, we summarize accumulated knowledge on anti-BK virus neutralizing antibodies as well as their clinical importance and therapeutic potential for kidney transplant recipients.</p>","PeriodicalId":17217,"journal":{"name":"Journal of The American Society of Nephrology","volume":null,"pages":null},"PeriodicalIF":10.3,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142361715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-09DOI: 10.1681/asn.0000000000000457
F. Helle, Aurélien Aubry, V. Morel, V. Descamps, Baptiste Demey, E. Brochot
The majority of the world’s adult population is latently infected by the BK polyomavirus. It causes asymptomatic infection in healthy individuals but emerged as a threat to kidney transplant recipients because of virus associated nephropathy caused by immunosuppressive therapy. In these conditions, when a functional cellular response is impaired by immunosuppression, neutralizing antibodies may play a major role, since they can directly prevent infection of target cells, independently of cell mediated immunity, by binding to the viral particles. Studying the contribution of anti-BK virus neutralizing antibodies in viral control has long been hampered by the lack of convenient in vitro models but major progress has been made in the last decade. The four BK virus genotypes have been demonstrated to behave as distinct serotypes. A low recipient neutralizing antibody titer against the donor’s serotype before kidney transplant has been significantly associated with BK virus replication after transplant. Different mechanisms exploited by the BK virus to evade neutralizing antibodies have been described. Recent studies also support the potential benefit of administering intravenous immunoglobulins or monoclonal neutralizing antibodies as a therapeutic strategy and, more interestingly, this could also be used as preventive or pre-emptive therapy, before advanced kidney damage has occurred. Besides, neutralizing antibodies could be induced by vaccination. In this review, we summarize accumulated knowledge on anti-BK virus neutralizing antibodies as well as their clinical importance and therapeutic potential for kidney transplant recipients.
世界上大多数成年人都潜伏感染了 BK 多瘤病毒。它可导致健康人无症状感染,但由于免疫抑制疗法导致的病毒相关性肾病,它已成为肾移植受者的一个威胁。在这些情况下,当细胞功能反应因免疫抑制而受损时,中和抗体可能会发挥重要作用,因为它们可以通过与病毒颗粒结合,直接阻止靶细胞感染,而不受细胞介导免疫的影响。长期以来,由于缺乏方便的体外模型,研究抗 BK 病毒中和抗体在病毒控制中的作用一直受到阻碍,但在过去十年中取得了重大进展。四种 BK 病毒基因型已被证明表现为不同的血清型。肾移植前受体针对供体血清型的中和抗体滴度低与移植后 BK 病毒复制有很大关系。已有研究描述了 BK 病毒逃避中和抗体的不同机制。最近的研究也支持将静脉注射免疫球蛋白或单克隆中和抗体作为一种治疗策略的潜在益处,更有趣的是,这也可以在肾脏出现晚期损伤之前作为预防性或先发制人的治疗。此外,还可以通过接种疫苗诱导中和抗体。在这篇综述中,我们总结了抗 BK 病毒中和抗体方面积累的知识及其对肾移植受者的临床重要性和治疗潜力。
{"title":"Neutralizing Antibodies Targeting BK Polyomavirus","authors":"F. Helle, Aurélien Aubry, V. Morel, V. Descamps, Baptiste Demey, E. Brochot","doi":"10.1681/asn.0000000000000457","DOIUrl":"https://doi.org/10.1681/asn.0000000000000457","url":null,"abstract":"\u0000 The majority of the world’s adult population is latently infected by the BK polyomavirus. It causes asymptomatic infection in healthy individuals but emerged as a threat to kidney transplant recipients because of virus associated nephropathy caused by immunosuppressive therapy. In these conditions, when a functional cellular response is impaired by immunosuppression, neutralizing antibodies may play a major role, since they can directly prevent infection of target cells, independently of cell mediated immunity, by binding to the viral particles. Studying the contribution of anti-BK virus neutralizing antibodies in viral control has long been hampered by the lack of convenient in vitro models but major progress has been made in the last decade. The four BK virus genotypes have been demonstrated to behave as distinct serotypes. A low recipient neutralizing antibody titer against the donor’s serotype before kidney transplant has been significantly associated with BK virus replication after transplant. Different mechanisms exploited by the BK virus to evade neutralizing antibodies have been described. Recent studies also support the potential benefit of administering intravenous immunoglobulins or monoclonal neutralizing antibodies as a therapeutic strategy and, more interestingly, this could also be used as preventive or pre-emptive therapy, before advanced kidney damage has occurred. Besides, neutralizing antibodies could be induced by vaccination. In this review, we summarize accumulated knowledge on anti-BK virus neutralizing antibodies as well as their clinical importance and therapeutic potential for kidney transplant recipients.","PeriodicalId":17217,"journal":{"name":"Journal of The American Society of Nephrology","volume":null,"pages":null},"PeriodicalIF":10.3,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141665097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Arteriovenous Access Creation Does Not Appear to Slow the Estimated Glomerular Filtration Rate Decline in Patients with CKD.","authors":"Abdel-Hay Tabcheh, Raphaël Coscas, Oriane Lambert, Bénédicte Stengel, Luc Frimat, Ziad Massy, Christian Combe, Murilo Guedes, Roberto Pecoits-Filho, Julie Boucquemont, Natalia Alencar De Pinho","doi":"10.1681/ASN.0000000000000443","DOIUrl":"https://doi.org/10.1681/ASN.0000000000000443","url":null,"abstract":"","PeriodicalId":17217,"journal":{"name":"Journal of The American Society of Nephrology","volume":null,"pages":null},"PeriodicalIF":10.3,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141559005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-05DOI: 10.1681/asn.0000000000000449
P. Rossing
{"title":"Experimental Designs for Multicomponent Interventions in Kidney and Cardiometabolic Diseases","authors":"P. Rossing","doi":"10.1681/asn.0000000000000449","DOIUrl":"https://doi.org/10.1681/asn.0000000000000449","url":null,"abstract":"","PeriodicalId":17217,"journal":{"name":"Journal of The American Society of Nephrology","volume":null,"pages":null},"PeriodicalIF":10.3,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141673651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-02DOI: 10.1681/asn.0000000000000432
G. Piccoli, G. Cabiddu
{"title":"Can Kidney Care Be Sustainable?","authors":"G. Piccoli, G. Cabiddu","doi":"10.1681/asn.0000000000000432","DOIUrl":"https://doi.org/10.1681/asn.0000000000000432","url":null,"abstract":"","PeriodicalId":17217,"journal":{"name":"Journal of The American Society of Nephrology","volume":null,"pages":null},"PeriodicalIF":10.3,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141687236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-02DOI: 10.1681/asn.0000000000000448
Michael G. Collins, CM Hawley, Stephen P. McDonald
{"title":"Nephrology Clinical Trials in Learning Health Systems","authors":"Michael G. Collins, CM Hawley, Stephen P. McDonald","doi":"10.1681/asn.0000000000000448","DOIUrl":"https://doi.org/10.1681/asn.0000000000000448","url":null,"abstract":"","PeriodicalId":17217,"journal":{"name":"Journal of The American Society of Nephrology","volume":null,"pages":null},"PeriodicalIF":10.3,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141684963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}